Editorial p187 A new dawn for osteoporosis drug development The Lancet Diabetes & Endocrinology +++ +...

Efficacy and safety of inclisiran in adolescents with heterozygous familial hypercholesterolaemia (ORION-16): a two-part, randomised, multicentre clinical trial Albert Wiegman, MD PhDa a.wiegman@amsterdamumc.nl ∙ Prof Amy L Peterson, MD MSb ∙ Prof Eric Bruckert, MDc ∙ Joep C Defesche, PhDd ∙ Anja Schweizer, PhDe ∙ Prof Jean Bergeron, MDf ∙ et al. https://www.thelancet.com/journals/landia/article/PIIS2213-8587(25)00351-1/abstract?utm_campaign=update-landia&utm_medium=email&dgcid=hubspot_update_feature_updatealerts_landia&_hsenc=p2ANqtz-8R51Rlrl3lS86kSOVGQpZUUkpkilDQBym6D53zF8w6sj1AcYtLCTQNiblkdXXPTknGyNNksphnNvJUOV4gsVsyIz3W_A&_hsmi=406700158&utm_content=406627328&utm_source=hs_email Effect of surgical versus conservative management on cardiovascular outcomes in patients with bilateral adrenal tumours and cortisol excess: an international, retrospective cohort study Elisabeth Nowak, MDa Elisabeth.Nowak@med.uni-muenchen.de ∙ Charlotte L Viëtor, MDb,c ∙ Prof Richard A Feelders, PhDb,d ∙ Johannes Hofland, PhDb ∙ Marta Araujo-Castro, PhDe,f ∙ César Minguéz Ojeda, MDg ∙ et al. https://www.thelancet.com/journals/landia/article/PIIS2213-8587(25)00302-X/abstract?utm_campaign=update-landia&utm_medium=email&dgcid=hubspot_update_feature_updatealerts_landia&_hsenc=p2ANqtz--D2uCgS1xapshAgsHLUZfohsd89nWva3F7caig-AL36ksUKE7Pel761oD25H77oJWvRN20EagVKnkE4bDhphlyFi379w&_hsmi=406700158&utm_content=406627328&utm_source=hs_email Temporal changes and genetic susceptibility to type 2 diabetes (1984–2019; HUNT): a longitudinal, population-based study Vera Vik Bjarkø, MDa,c ∙ Brooke N Wolford, PhDa ∙ Eirin B Haug, PhDa ∙ Lars C Stene, PhDd ∙ Sofia Carlsson, PhDe ∙ Prof Arnulf Langhammer, MDf,g ∙ et al. https://www.thelancet.com/journals/landia/article/PIIS2213-8587(25)00322-5/abstract?utm_campaign=update-landia&utm_medium=email&dgcid=hubspot_update_feature_updatealerts_landia&_hsenc=p2ANqtz--peYeXFz-Z4E5bTcnS-VCWypFWEfDw4BZACsxoA28B3Bu085lVN_Lwj9iEr8ZZmis9GxvexTeHnMxLpBe_UlL5OeUHBA&_hsmi=406700158&utm_content=406627328&utm_source=hs_email Editorial p187 A new dawn for osteoporosis drug development The Lancet Diabetes & Endocrinology https://www.thelancet.com/journals/landia/issue/vol14no3/PIIS2213-8587(26)X2001-0